CAS: 487-49-0; 2',4'-Dihydroxy-2-(4-Methoxyphenyl)Acetophenone

该化合物是有机化合物,具有复杂的芳芳香结构,该物质具有一个氯酮功能组,由异丙酮运动和两个苯酚组表示,其中一个在2和4个位置上具有氢氧基替代成分,增强了其再活性和氢联结潜力.第二苯环上存在甲氧基组,有助于其有机溶剂的整体稳定性和溶解性.该化合物经常因其潜在的生物活动(包括抗氧化剂特性)受到研究,因为存在多种氢氧基组.其分子结构允许与生物系统进行各种互动,使其对药用化学和药理学感兴趣.此外,其物理特性,如熔点和溶解性,可以根据其分析的纯度和具体条件而有所不同.

结构式图片

欧盟法规

ECHA物质C&L通报

合成工艺路线路线简述

    📜刺芒柄花素置于sodium Hydroxide体系中,化学反应生成 1-(2,4-二羟基苯基)-2-(4-甲氧基苯基)乙酮
    参考文献:Virtanen; Hietala,Acta Chemica Scandinavica (1947),1958,Vol. 12,P. 579
    标题:Virtanen; Hietala,Acta Chemica Scandinavica (1947),1958,Vol. 12,P. 579

    海关参考信息

    专利信息


    专利号:US-8476313-B2
    优先权日:2004-08-26
    标 题:Heteroaryl-containing isoflavones as aromatase inhibitors
    发明人:BRUEGGEMEIER ROBERT W; KIM YOUNG-WOO; HACKETT JOHN C
    权利人:BRUEGGEMEIER ROBERT W; KIM YOUNG-WOO; HACKETT JOHN C; UNIV OHIO STATE RES FOUND
    摘要:Compounds and methods useful for treating and prevention of cancer, particularly hormone-dependent breast cancer. Provided are compounds of formula I: n nwherein X is selected from O, N, S, SO, SO 2 , and S(CH 2 ) n , wherein n=1-10; R 1 and R 2 may be the same or different and are selected from H, OH, OCH 3 , OCH 2 CH 3 , OCH 2 C 6 H 5 , NH 2 , NHCH 3 , N(CH 3 ) 2 , CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , C(CH 3 ) 3 , NO 2 , F, Cl, Br, CF 3 , SH, SCH 3 , SCH 2 CH 3 , OCOCH 3 , OCOC(CH 3 ) 3 , OCOCH 2 COOH, and CN; and R 3 is a nitrogen-containing heterocyclic ring. Also provided are method for treating or preventing cancer in a subject by administering a therapeutically effective amount of a heteroaryl-containing isoflavone, or a pharmaceutically acceptable salt or prodrug thereof, to a subject in need of treatment. Also provided is a method for the synthesis of 2-substituted isoflavones by first reacting deoxybenzoins with a phase transfer catalyst to provide a 2-(alkylthio)isoflavone; second deprotecting the 2-(alkylthio)isoflavone; and third applying selective debenzylation to form the final compound.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Sasso EM, Muraki K, Eaton-Fitch N, Smith P, Jeremijenko A, Griffin P, Marshall-Gradisnik S. Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target. Front Immunol. 2024 May 3;15:1264702. doi: 10.3389/fimmu.2024.1264702.
    2: Langen KR, Dantzler HA, de Barcellos-Filho PG, Kline DD. Hypoxia augments TRPM3-mediated calcium influx in vagal sensory neurons. Auton Neurosci. 2023 Jul;247:103095. doi: 10.1016/j.autneu.2023.103095. Epub 2023 Apr 29.
    3: Sasso EM, Muraki K, Eaton-Fitch N, Smith P, Lesslar OL, Deed G, Marshall- Gradisnik S. Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients. Mol Med. 2022 Aug 19;28(1):98. doi: 10.1186/s10020-022-00528-y.

    合成参考文献


    参考文献:10.1038/ncb3255
    摘要:Lin R, Elf S, Shan C, Kang HB, Ji Q, Zhou L, Hitosugi T, Zhang L, Zhang S, Seo JH, Xie J, Tucker M, Gu TL, Sudderth J, Jiang L, Mitsche M, DeBerardinis RJ, Wu S, Li Y, Mao H, Chen PR, Wang D, Chen GZ, Hurwitz SJ, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Lei Q, Brat DJ, Ye K, Boggon TJ, He C, Kang S, Fan J, Chen J. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol. 2015 Nov;17(11):1484–96.
    摘要:Ross et al. JASMS 2022; 33; 1061-1072. DOI:10.1021/jasms.2c00111
    摘要:
    摘要:Marsini, M. A.; Pettus, T. R. R., Science of Synthesis, (2007) 31, 444.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知